2021

Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma

Hussein A. Tawbi, MD, PhD, deputy chair, professor, director of melanoma clinical research and early drug development, director of personalized cancer therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of relatlimab plus nivolumab (Opdivo) in advanced melanoma.

Read More
MRV News
Melanoma News
Archive
Menu